Development of a Disease Activity Index for the Assessment of VEXAS Syndrome (VEXAS-DAI)

Download Poster (434.4 KB)

Publication

EULAR •
14 June, 2025 •
•

Variations in Chronic Refractory Gout Management between Rheumatologists and Nephrologists

Kenneth Saag , Nana Kragh, Amod Athavale, Bhavisha Desai, Amal Gulaid, Abiola Oladapo, Brittany Smith, Hyon Choi

Available materials

Poster

Publication

EULAR •
14 June, 2025 •
•

PAXIS: A Randomized, Double-Blind, Placebo-Controlled, Dose Finding Phase 2 Study (Part 1) Followed by an Open-Label Period (Part 2) to Assess the Efficacy and Safety of Pacritinib in Patients with VEXAS Syndrome

David B. Beck, Mael Heiblig, Sinisa Savic, Marcela A. Ferrada, Arsene Mekinian, Onima Chowdhury, Danielle Hammond, Lachelle D. Weeks, Carmelo Gurnari, Yohei Kirino , Sophie Georgin-Lavialle, Sarah A. Buckley, Bryan G. Harder, Sandra Goble, Matthew J. Koster

Available materials

Poster

Publication

EULAR •
13 June, 2025 •
•

Development of a Consensus Definition of VEXAS Flare for Use in Clinical Research

Lachelle D. Weeks, Danielle Hammond, Sinisa Savic, Mael Heiblig, Onima Chowdhury, Arsene Mekinian, Carmelo Gurnari, Radhakrishnan Ramchandren, Sophie Georgin-Lavialle, Marcela A. Ferrada, Sarah A. Buckley, Bryan G. Harder, Sandra Goble, David B. Beck, Matthew J. Koster

Available materials

Poster

Publication

ACR •
29 October, 2025 •
•

PAXIS: A Randomized, Double-Blind, Placebo-Controlled, Dose Finding Phase 2 Study (Part 1) Followed by an Open-Label Period (Part 2) to Assess the Efficacy and Safety of Pacritinib in Patients with VEXAS Syndrome

Available materials

Oral Presentation

Publication

ACR •
26 October, 2025 •
•